Nanobiotix Files January 2025 6-K Report
Ticker: NBTX · Form: 6-K · Filed: Jan 21, 2025 · CIK: 1760854
Sentiment: neutral
Topics: regulatory-filing, 6-K, foreign-private-issuer
TL;DR
Nanobiotix (NBTX) filed its January 6-K, confirming 20-F annual report filing.
AI Summary
Nanobiotix S.A. filed a Form 6-K on January 21, 2025, reporting for the month of January 2025. The company, based in Paris, France, is a pharmaceutical preparations company. This filing indicates they are submitting their report under the 1934 Act and will file annual reports under Form 20-F.
Why It Matters
This filing provides routine updates for investors and regulatory bodies regarding Nanobiotix S.A.'s ongoing compliance and reporting status.
Risk Assessment
Risk Level: low — This is a routine periodic filing with no new material financial or operational information disclosed.
Key Players & Entities
- Nanobiotix S.A. (company) — Filer of the report
- 001-39777 (company) — SEC File Number
- 20250121 (date) — Filing date
- January 2025 (date) — Reporting period
- 60 Rue de Wattignies 75012 Paris, France (company) — Principal executive office address
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to provide information that the issuer would be required to disclose to its home country security holders.
Which annual report form does Nanobiotix S.A. file?
Nanobiotix S.A. indicates it files annual reports under cover of Form 20-F.
What is the SEC file number for Nanobiotix S.A.?
The SEC file number for Nanobiotix S.A. is 001-39777.
Where is Nanobiotix S.A. headquartered?
Nanobiotix S.A. is headquartered at 60 Rue de Wattignies, 75012 Paris, France.
What is the SIC code for Nanobiotix S.A.?
The Standard Industrial Classification (SIC) code for Nanobiotix S.A. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 172 words · 1 min read · ~1 pages · Grade level 9.1 · Accepted 2025-01-21 06:00:09
Filing Documents
- f6k_012025.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 9KB
- 0001171843-25-000325.txt ( ) — 15KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Nanobiotix S.A. (Registrant) Date: January 21, 2025 /s/ Bart Van Rhijn Bart Van Rhijn Chief Financial Officer